Causaly, an AI platform for drug discovery and biomedical research, raises $60M

Artificial intelligence has been a big theme in the world of health and medical research, and specifically in the area of drug discovery. Today, another hopeful in the space is announcing a funding round to expand its own contribution to the field. Causaly, a London startup that has built an AI platform to help researchers accelerate the development and testing of drugs, has raised $60 million, a Series B that will be going towards R&D and to continue building out its team.
ICONIQ Growth — the growth stage fund affiliated with the iconic investment firm of the same name — is le

リンク元